{
    "clinical_study": {
        "@rank": "69000", 
        "acronym": "Focus-101", 
        "arm_group": [
            {
                "arm_group_label": "Arm I", 
                "arm_group_type": "Experimental", 
                "description": "Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV; Second administration: Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV"
            }, 
            {
                "arm_group_label": "Arm II", 
                "arm_group_type": "Active Comparator", 
                "description": "First administration: Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Second administration: Acyclovir for Injection 0.25g+ 0.9% Sodium Chloride Injection 250ml, IV"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of Foscarnet Sodium and\n      Sodium Chloride Injection in patients with herpes zoster, and observe incidence of\n      Postherpetic neuralgia"
        }, 
        "brief_title": "Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster", 
        "condition": "Herpes Zoster", 
        "condition_browse": {
            "mesh_term": "Herpes Zoster"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.Patients with clinical diagnosis of Herpes Zoster, and able to be enrolled into the\n        study \u2264 72 hours from appearance of rash; 2.18-65 years old, men and women; 3.VAS score\u22654;\n        4.Patients haven't receive any antiviral medication before enrollment; 5.Patients able to\n        understand the study procedures, agree to participate and give written consent.\n\n        Exclusion Criteria:\n\n          1. Patients with history of allergy to Foscarnet Sodium or Acyclovir;\n\n          2. Other combined infection (bacteria, fungi)\n\n          3. Severe decline in immune function, or long-term use of corticosteroid and\n             immunosuppressor\n\n          4. Serious liver or renal function abnormalities (Aspartate Transaminase(AST) or alanine\n             transaminase(ALT) \u2265 2.5x upper limits of normal(ULN), Creatinine(Cr) or Blood urea\n             nitrogen(BUN)\u2265 1x ULN)\n\n          5. Women who are pregnant or lactating, and women of childbearing potential failed to\n             use an adequate method of contraception to avoid pregnancy;\n\n          6. Patients using other antiviral drugs;\n\n          7. Long-term use of non-steroid anti-inflammatory drug, tricyclic antidepressant,\n             anti-epileptic drugs or analgesic\n\n          8. Current malignant tumor;\n\n          9. Patients investigators consider as inappropriate to participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151240", 
            "org_study_id": "cttq-focus-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I", 
                "intervention_name": "Foscarnet Sodium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm II", 
                "intervention_name": "Acyclovir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acyclovir", 
                "Foscarnet", 
                "Phosphonoacetic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "herpes zoster, Foscarnet Sodium, Acyclovir, Postherpetic neuralgia", 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "13911815813@126.com", 
                "last_name": "Jianzhong Zhang, Doctor", 
                "phone": "86-18610275899"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100044"
                }, 
                "name": "Peking University People's Hospital"
            }, 
            "investigator": {
                "last_name": "Jianzhong Zhang, Doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China", 
        "overall_contact": {
            "email": "13911815813@126.com", 
            "last_name": "Jianzhong Zhang, Doctor", 
            "phone": "86-18610275899"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Effective rate = (No. of patients achieving recovery+ markedly improvement)/Total patients No.\u00d7100%.\nRecovery: curative index\u226590%; Markedly improved: curative index 60%-89%; Improved: curative index 20%-59%; Ineffective: curative index\uff1c20%. Where Curative Index= (patient's pre-treatment condition score - post-treatment condition score)/pre-treatment condition score \u00d7100%", 
            "measure": "Effective rate", 
            "safety_issue": "No", 
            "time_frame": "8th days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151240"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "9868672", 
                "citation": "Breton G, Fillet AM, Katlama C, Bricaire F, Caumes E. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin Infect Dis. 1998 Dec;27(6):1525-7. PubMed"
            }, 
            {
                "PMID": "1646585", 
                "citation": "Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB, Mills J, Biron KK. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med. 1991 Jul 1;115(1):19-21. PubMed"
            }
        ], 
        "secondary_outcome": [
            {
                "measure": "Incidence of Postherpetic neuralgia", 
                "safety_issue": "No", 
                "time_frame": "3rd month"
            }, 
            {
                "measure": "number of participants with adverse event and serious adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }
        ], 
        "source": "Cttq", 
        "sponsors": {
            "collaborator": {
                "agency": "Peking University People's Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Cttq", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}